Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
In January of this year, partial responses in liver, melanoma, gastro-esophageal junction, and head and neck cancers were reported.
- In January of this year, partial responses in liver, melanoma, gastro-esophageal junction, and head and neck cancers were reported.
- In 2019, Adaptimmune announced agreements with Alpine Immune Sciences and Noile-Immune to develop further next-generation products.
- Adrian Rawcliffe assumed the role of Chief Executive Officer effective September 1, 2019 and John Lunger became Chief Patient Supply Officer effective August 1, 2019.
- Financial Results for the fourth quarter and year ended December 31, 2019
Cash / liquidity position: As of December 31, 2019, Adaptimmune had cash and cash equivalents of $50.4million and Total Liquidity1 of $89.5 million.